NOSTEROID YALLIG‘LANISHGA QARSHI DORI VOSITALARINING XAVFSIZ QO‘LLANILISHI: GASTROINTESTINAL VA YURAK-QON TOMIR ASORATLARINING OLDINI OLISH
Keywords:
nosteroid yallig‘lanishga qarshi dori vositalari, NYAQV, gastrointestinal asoratlar, peptik yara, me’da-ichak qon ketishi, yurak-qon tomir xavfi, COX-1, COX-2, proton pompa ingibitorlari, gastroproteksiya, arterial gipertenziya, buyrak faoliyati, dori vositalari xavfsizligi.Abstract
Nosteroid yallig‘lanishga qarshi dori vositalari (NYAQV) og‘riq, yallig‘lanish va isitmani kamaytirish maqsadida klinik amaliyotda keng qo‘llaniladi. Ularning terapevtik samaradorligiga qaramay, gastrointestinal tizim, yurak-qon tomir tizimi va buyraklarga salbiy ta’sir ko‘rsatishi klinik farmakologiyaning muhim muammolaridan biri hisoblanadi. NYAQV bilan bog‘liq eng jiddiy asoratlar qatoriga me’da va o‘n ikki barmoq ichak yaralari, gastrointestinal qon ketishi, arterial bosimning oshishi, suyuqlik tutilishi, yurak yetishmovchiligining zo‘rayishi, miokard infarkti va insult xavfining ortishi kiradi. Bunday asoratlar preparatning farmakologik xususiyatlari bilan bir qatorda, doza, davolash davomiyligi, bemorning yoshi, hamroh kasalliklari va bir vaqtda qabul qilinayotgan boshqa dori vositalariga ham bog‘liq. Maqolaning maqsadi NYAQVning gastrointestinal va yurak-qon tomir xavflarini shakllantiruvchi mexanizmlarni tahlil qilish hamda xavfsiz farmakoterapiyaning klinik tamoyillarini yoritishdan iborat. Maqolada siklooksigenaza-1 va siklooksigenaza-2 fermentlarini ingibitsiya qilish mexanizmi, gastrointestinal shilliq qavat himoyasining susayishi, trombotsitlar faoliyati va buyrak gemodinamikasidagi o‘zgarishlar ko‘rib chiqiladi. Shuningdek, bemorning individual xavf profilini baholash, proton pompa ingibitorlari yordamida gastroproteksiya, selektiv COX-2 ingibitorlarini tanlash, arterial bosim va buyrak faoliyatini monitoring qilish masalalari yoritiladi. Tahlil natijalari NYAQVni xavfsiz qo‘llashda yagona universal preparat tanlashdan ko‘ra, gastrointestinal, yurak-qon tomir va buyrak xavflarini birgalikda baholash muhimligini ko‘rsatadi. Eng kam samarali dozani eng qisqa zarur muddat qo‘llash, bir nechta NYAQVni bir vaqtda buyurmaslik, gastroproteksiyani tegishli xavf omillari mavjud bemorlarda qo‘llash va davolash zaruratini muntazam qayta baholash asoratlar ehtimolini kamaytirishga xizmat qiladi.
References
1. Szeto C.C., Machida H., Kanda H., et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut. 2020;69(4):617–629. doi:10.1136/gutjnl-2019-319300.
2. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet. 2013;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9.
3. Bhala N., Emberson J., Merhi A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet. 2013;382(9894):769–779.
4. Practice Advisory on the Appropriate Use of NSAIDs in Primary Care. Journal of Pain Research. 2020;13:1925–1939.
5. U.S. Food and Drug Administration. Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Drug Safety and Prescribing Information. Silver Spring, MD: FDA.
6. National Institute for Health and Care Excellence. Osteoarthritis in Over 16s: Diagnosis and Management. NICE Guideline NG226. London: NICE; 2022.
7. National Institute for Health and Care Excellence. Gastro-oesophageal Reflux Disease and Dyspepsia in Adults: Investigation and Management. Clinical Guideline CG184. London: NICE.
8. Lanza F.L., Chan F.K.L., Quigley E.M.M. Guidelines for prevention of NSAID-related ulcer complications. The American Journal of Gastroenterology. 2009;104(3):728–738. doi:10.1038/ajg.2009.115.
9. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews. 2002;(4). doi:10.1002/14651858.CD002296.
10. U.S. Food and Drug Administration. FDA Strengthens Warning That Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Can Cause Heart Attacks or Strokes. Drug Safety Communication. Silver Spring, MD: FDA; 2015.
11. Warner T.D., Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. The FASEB Journal. 2004;18(7):790–804. doi:10.1096/fj.03-0645rev.
12. Grosser T., Ricciotti E., FitzGerald G.A. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends in Pharmacological Sciences. 2017;38(8):733–748.
13. Harirforoosh S., Asghar W., Jamali F. Adverse effects of nonsteroidal anti-inflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. Journal of Pharmacy & Pharmaceutical Sciences. 2013;16(5):821–847.
14. U.S. National Library of Medicine. Naproxen: Prescribing Information. DailyMed. Bethesda, MD: National Library of Medicine.
15. European Medicines Agency. Non-steroidal Anti-inflammatory Drugs (NSAIDs): Cardiovascular Safety Review. Amsterdam: EMA.
